Antibiotics for acute laryngitis in adults

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 12, 2015, Pages

  Reveiz, Ludovic ^a   Cardona, Andrés Felipe ^b  

^a Free time independent Cochrane reviewer   (United States)

^b HOSPITAL UNIVERSITARIO FUNDACIÓN SANTA FE DE BOGOTÁ   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BIOPAROX; CLACID; CLARITHROMYCIN; ERYTHROMYCIN; FUSAFUNGINE; PENICILLIN V; PLACEBO; ANTIINFECTIVE AGENT;

ADULT; ADVERSE OUTCOME; ALLERGIC REACTION; ANTIBIOTIC THERAPY; CLINICAL EFFECTIVENESS; COUGHING; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HEARING IMPAIRMENT; HIGH RISK POPULATION; HOARSENESS; HUMAN; LARYNGITIS; LIVER TOXICITY; LOW RISK POPULATION; MORAXELLACEAE INFECTION; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RASH; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SYMPTOM; SYSTEMATIC REVIEW; VOICE; VOICE DISORDER; ACUTE DISEASE; FUSARIUM; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ACUTE DISEASE; ADULT; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; ERYTHROMYCIN; FUSARIUM; HUMANS; LARYNGITIS; PENICILLIN V; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84945390479     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD004783.pub5     Document Type: Review

References (65)

1. Rafalskiy VV, Gurevitch AS, Otvagin IV, Dovgan EVA. Randomized comparative study of 7-days courses of fuzafungine vs. fuzafungine and clarithromycin in patients with acute laryngitis. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) of the American Society for Microbiology. Available at: http://www.icaaconline.com/php/icaac2013abstracts/data/papers/2012/L1/2012_L1-299.htm (accessed February 3, 2015), 2012; Vol. 52:L1299.
2. Schalén L, Christensen P, Eliasson I, Fex S, Kamme C, Schalen C. Inefficacy of penicillin V in acute laryngitis in adults. Evaluation from results of double-blind study. Annals of Otology, Rhinology, and Laryngology 1985;94(1 Pt 1):14-7.
3. Schalén L, Eliasson I, Kamme C, Schalen C. Erythromycin in acute laryngitis in adults. Annals of Otology, Rhinology, and Laryngology 1993;102(3 Pt 1):209-14.
4. Schalén L, Eliasson I, Fex S, Kamme C, Schalen C. Acute laryngitis in adults: results of erythromycin treatment. Acta Oto-Laryngologica. Supplement 1992;492:55-7.
5. Altman DG. Types of data. In: Altman DG editor(s). Practical Statistics for Medical Research. Eighth. Chapman & Hall/CRC, 1999:10-18.
6. Arnold SR, Straus SE. Interventions to improve antibiotic prescribing practices in ambulatory care. Cochrane Database of Systematic Reviews 2005, Issue 4. [DOI: 10.1002/14651858.CD003539.pub2]
7. Arroll B, Kenealy T. Antibiotics for the common cold and acute purulent rhinitis. Cochrane Database of Systematic Reviews 2013, Issue 6. [DOI: 10.1002/14651858.CD000247.pub3]
8. Berlin J. Does blinding readers affect the results of meta-analysis? University of Pennsylvania Meta-analysis Blinding Study Group. Lancet 1997;350:185-6.
9. Bertino JS. Cost burden of viral respiratory infections: issues for formulary decision makers. American Journal of Medicine 2002;112(Suppl 6A):42-9.
10. Birnbaum HG, Morley M, Greenberg PE, Colice GL. Economic burden of respiratory infections in an employed population. Chest 2002;122(2):603-11.
11. Castro AA, Clark OAC, Atallah A. Optimal search strategy for clinical trials in the Latin American and Caribbean Health Science Literature Database (LILACS). São Paulo Medical Journal 1997;115:1423-6.
12. Catlin BW. Branhamella catarrhalis: an organism gaining respect as a pathogen. Clinical Microbiology Reviews 1990;3:293-320.
13. Cherry DK, Burt CW, Woodwell DA. National Ambulatory Medical Care Survey: 2001 summary. Advance Data. http://www.cdc.gov/nchs/data/ad/ad338.pdf (accessed 24 September 2003) 2003; Vol. 337:1-44.
14. Cohen SM, Kim J, Roy N, Asche C, Courey M. Direct health care costs of laryngeal diseases and disorders. Laryngoscope 2012;122(7):1582-8.
15. Danielides V, Nousia CS, Patrikakos G, Bartzokas A, Lolis CJ, Milionis HJ, et al. Effect of meteorological parameters on acute laryngitis in adults. Acta Oto-Laryngologica 2002;122(6):655-60.
16. DiGiovanni C, Riley TV, Hoyne GF, Yeo R, Cooksey P. Respiratory tract infections due to Branhamella catarrhalis: epidemiological data from Western Australia. Epidemiology and Infection 1987;99:445-53.
17. Ejlertsen T, Thisted E, Ebbesen F, Olesen B, Renneberg J. Branhamella catarrhalis in children and adults. A study of prevalence, time of colonisation, and association with upper and lower respiratory tract infections. Journal of Infection 1994;29:23-31.
18. FDA. PCE® (erythromycin particles in tablets). Available at: http://www.fda.gov/medwatch/SAFETY/2004/mar_PI/PCE_PI.pdf (accessed July 2004).
19. Fung CP, Powell M, Seymour A, Yuan M, Williams JD. The antimicrobial susceptibility of Moraxella catarrhalis isolated in England and Scotland in 1991. Journal of Antimicrobial Chemotherapy 1992;30:47-55.
20. Gonzales R, Bartlett JG, Besser RE, Hickner JM, Hoffman JR, Sande MA, et al. Principles of appropriate antibiotic use for treatment of nonspecific upper respiratory tract infections in adults: background. Annals of Emergency Medicine 2001;37(6):698-702.
21. Gonzales R, Malone DC, Maselli JH, Sande MA. Excessive antibiotic use for acute respiratory infections in the United States. Clinical Infectious Disease 2001;33(6):757-62.
22. Greiner O, Day PJ, Altwegg M, Nadal D. Quantitative detection of Moraxella catarrhalis in nasopharyngeal secretions by real-time PCR. Journal of Clinical Microbiology 2003;41(4):1386-90.
23. Guyatt GH, Oxman AD, Santesso N, Helfand M, Vist G, Kunz R, et al. GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes. Journal of Clinical Epidemiology 2013;66(2):158-72.
24. Hashiguchi K, Ogawa H, Kazuyama Y. Seroprevalence of Chlamydia pneumoniae infections in otolaryngeal diseases. Journal of Laryngology and Otology 1992;106:208.
25. Higgins PB. Viruses associated with acute respiratory infections 1961-71. Journal of Hygiene 1974;72(3):425-32.
26. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available from www.cochrane-handbook.org. Chichester, UK: Wiley-Blackwell, 2011.
27. Hol C, Schalen C, Verduin CM, Van Dijke EE, Verhoef J, Fleer A. Moraxella catarrhalis in acute laryngitis: infection or colonization?. Journal of Infectious Diseases 1996;174(3):636-8.
28. Jacobs MR, Bajaksouzian S, Windau A, Good CE, Lin G, Pankuch GA, et al. Susceptibility of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis to 17 oral antimicrobial agents based on pharmacodynamic parameters: 1998-2001 US Surveillance Study. Clinics in Laboratory Medicine 2004;24:503-30.
29. Jorgensen JH, Doern GV, Maher LA, Howell AW, Redding JS. Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States. Antimicrobial Agents and Chemotherapy 1990;34(11):2075-80.
30. Koufman JA. Infectious and inflammatory diseases of the larynx. In: Ballenger JJ, Snow JB editor(s). Otorhinolaryngology. Fifteenth. Philadelphia: Williams and Wilkins (Lea & Febiger), 1996:535-55.
31. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
32. Lemiengre MB, van Driel ML, Merenstein D, Young J, De Sutter AI. Antibiotics for clinically diagnosed acute rhinosinusitis in adults. Cochrane Database of Systematic Reviews 2012, Issue 10. [DOI: 10.1002/14651858.CD006089.pub4]
33. Lund VJ, Grouin JM, Eccles R, Bouter C, Chabolle F. Efficacy of fusafungine in acute rhinopharyngitis: a pooled analysis. Rhinology 2004;42(4):207-12.
34. Malmvall BE, Molstad S, Darelid J, Hiselius A, Larsson L, Swanberg J, et al. Reduction of antibiotics sales and sustained low incidence of bacterial resistance: report on a broad approach during 10 years to implement evidence-based indications for antibiotic prescribing in Jonkoping County, Sweden. Quality Management in Health Care 2007;16(1):60-7.
35. Mazzaglia G, Greco S, Lando C, Cucinotta G, Caputi AP, Mazzaglia G. Adult acute upper respiratory tract infections in Sicily: pattern of antibiotic drug prescription in primary care. Journal of Antimicrobial Chemotherapy 1998;41(2):259-66.
36. McAuley L, Pham B, Tugwell P, Moher D. Does the inclusion of grey literature influence estimates of intervention effectiveness reported in meta-analyses?. Lancet 2000;356:1228-31.
37. McAvoy B, Davis P, Raymont A, Gribben B. The Waikato Medical Care Survey. New Zealand Medical Journal 1994;107:387-433.
38. McCaig LF, Hughes JM. Trends in antimicrobial drug prescribing among office-based physicians in the United States. JAMA 1995;273(3):214-9.
39. McGregor A, Dovey S, Tilyard M. Antibiotic use in upper respiratory tract infections in New Zealand. Family Practice 1995;12:166-70.
40. Periti P, Mazzei T, Mini E, Novelli A. Adverse effects of macrolide antibacterials. Drug Safety 1993;9(5):346-64.
41. Post JC, Preston RA, Aul JJ, Larkins-Pettigrew M, Rydquist-White J, Anderson KW, et al. Molecular analysis of bacterial pathogens in otitis media with effusion. JAMA 1995;273:1598-604.
42. Post JC, White J, Aul JJ, Zavoral T, Wadowsky RM, Zhang Y, et al. Development and validation of a multiplex PCR-based assay for the upper respiratory tract bacterial pathogens Haemophilus influenzae, Streptococcus pneumoniae, and Moraxella catarrhalis. Molecular Diagnosis 1996;1:29-39.
43. Postma GN, Koufman JA. Laryngitis. In: Bailey BJ editor(s). Head and Neck Surgery - Otolaryngology. Second Edition. Philadelphia: Lippincott-Raven, 1998:731-9.
44. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
45. Schalen L, Christensen P, Kamme C, Miorner H, Pettersson KI, Schalen C. High isolation rate of Branhamella catarrhalis from the nasopharynx in adults with acute laryngitis. Scandinavian Journal of Infectious Diseases 1980;12(4):277-80.
46. Schalen L. Acute laryngitis in adults: diagnosis, etiology, treatment. Acta Oto-Laryngologica 1988;449:31.
47. Spiegel JR, Hawkshaw M, Markiewicz A, Sataloff RT. Acute laryngitis. Ear, Nose, and Throat Journal 2000;79(7):488.
48. Spinks A, Glasziou PP, Del Mar C. Antibiotics for sore throat. Cochrane Database of Systematic Reviews 2013, Issue 11. [DOI: 10.1002/14651858.CD000023.pub4]
49. Steinman MA, Landefeld CS, Gonzales R. Predictors of broad-spectrum antibiotic prescribing for acute respiratory tract infections in adult primary care. JAMA 2003;289(6):719-25.
50. Steinman MA, Gonzales R, Linder JA, Landefeld CS. Changing use of antibiotics in community-based outpatient practice, 1991-1999. Annals of Internal Medicine 2003;138(7):525-33.
51. Steinman MA, Yang KY, Byron SC, Maselli JH, Gonzales R. Variation in outpatient antibiotic prescribing in the United States. American Journal of Managed Care 2009;15(12):861-8.
52. Sun C, Jew S, Dasta SL. Osteopathic physicians in the United States: antibiotic prescribing practices for patients with nonspecific upper respiratory tract infections. Journal of the American Osteopathic Association 2006;106(8):450-5.
53. Vaughan CW. Current concepts in otolaryngology: diagnosis and treatment of organic voice disorders. New England Journal of Medicine 1982;307(14):863-6.
54. Verduin CM, Hol C, Fleer A, van Dijk H, van Belkum A. Moraxella catarrhalis: from emerging to established pathogen. Clinical Microbiology Reviews 2002;15(1):125-44.
55. Wallace RJ, Nash DR, Steingrube VA. Antibiotic susceptibilities and drug resistance in Moraxella (Branhamella) catarrhalis. American Journal of Medicine 1990;88:46S-50S.
56. Wang H, Yu YS, Liu Y, Li HY, Hu BJ, Sun ZY, et al. Resistance surveillance of common community respiratory pathogens isolated in China, 2002-2003 (abstract). Zhonghua Jie He He Hu Xi Za Zhi 2004;27(3):155-60.
57. WHO. Upper respiratory tract infections. http://apps.who.int/medicinedocs/en/d/Js5406e/3.html (accessed 24 September 2003) 2003.
58. World Health Organization. Antimicrobial resistance: global report on surveillance. Available at http://apps.who.int/iris/bitstream/10665/112642/1/9789241564748_eng.pdf (accessed 3 February 2015) 2014.
59. Wirtz VJ, Dreser A, Gonzales R. Trends in antibiotic utilization in eight Latin American countries, 1997-2007. Revista Panamericana de Salud Pública 2010;27(3):219-25.
60. Ospina EG, Reveiz L, Cardona AF, Granados CE, Osorio JV. Antibiotics for acute laryngitis in adults. Cochrane Database of Systematic Reviews 2004, Issue 2. [DOI: 10.1002/14651858.CD004783]
61. Reveiz L, Cardona AF, Ospina EG. Antibiotics for acute laryngitis in adults. Cochrane Database of Systematic Reviews 2005, Issue 1. [DOI: 10.1002/14651858.CD004783.pub2]
62. Reveiz L, Cardona AF, Ospina EG. Antibiotics for acute laryngitis in adults. Cochrane Database of Systematic Reviews 2007, Issue 2. [DOI: 10.1002/14651858.CD004783.pub3]
63. Reveiz L, Cardona AF, Ospina EG. Antibiotics for acute laryngitis in adults. Cochrane Database of Systematic Reviews 2009, Issue 2. [DOI: 10.1002/14651858.CD004783.pub3]
64. Reveiz L, Cardona AF, Ospina EG. Antibiotics for acute laryngitis in adults. Cochrane Database of Systematic Reviews 2011, Issue 5. [DOI: 10.1002/14651858.CD004783.pub3]
65. Reveiz L, Cardona AF. Antibiotics for acute laryngitis in adults. Cochrane Database of Systematic Reviews 2013, Issue 3. [DOI: 10.1002/14651858.CD004783.pub4]